Aim: The nationwide Danish Testicular Cancer database consists of a retrospective research database (DaTeCa database) and a prospective clinical database (Danish Multidisciplinary Cancer Group [DMCG] DaTeCa database). The aim is to improve the quality of care for patients with testicular cancer (TC) in Denmark, that is, by identifying risk factors for relapse, toxicity related to treatment, and focusing on late effects.
Study Population: All Danish male patients with a histologically verified germ cell cancer diagnosis in the Danish Pathology Registry are included in the DaTeCa databases. Data collection has been performed from 1984 to 2007 and from 2013 onward, respectively.
Main Variables And Descriptive Data: The retrospective DaTeCa database contains detailed information with more than 300 variables related to histology, stage, treatment, relapses, pathology, tumor markers, kidney function, lung function, etc. A questionnaire related to late effects has been conducted, which includes questions regarding social relationships, life situation, general health status, family background, diseases, symptoms, use of medication, marital status, psychosocial issues, fertility, and sexuality. TC survivors alive on October 2014 were invited to fill in this questionnaire including 160 validated questions. Collection of questionnaires is still ongoing. A biobank including blood/sputum samples for future genetic analyses has been established. Both samples related to DaTeCa and DMCG DaTeCa database are included. The prospective DMCG DaTeCa database includes variables regarding histology, stage, prognostic group, and treatment.
Conclusion: The DMCG DaTeCa database has existed since 2013 and is a young clinical database. It is necessary to extend the data collection in the prospective database in order to answer quality-related questions. Data from the retrospective database will be added to the prospective data. This will result in a large and very comprehensive database for future studies on TC patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094651 | PMC |
| http://dx.doi.org/10.2147/CLEP.S99493 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Hearing Loss in Testicular Cancer Patients after Cisplatin-Based Chemotherapy.
Cancers (Basel)
August 2023
Department of Health Technology, Technical University of Denmark, 2800 Kongens Lyngby, Denmark.
Testicular cancer is predominantly curable, but the long-term side effects of chemotherapy have a severe impact on life quality. In this research study, we focus on hearing loss as a part of overall chemotherapy-induced ototoxicity. This is a unique approach where we combine clinical data from the acclaimed nationwide Danish Testicular Cancer (DaTeCa)-Late database.
View Article and Find Full Text PDFA Validated Algorithm for Register-Based Identification of Patients with Relapse of Clinical Stage I Testicular Cancer.
Clin Epidemiol
April 2023
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Article Synopsis
- - The DaTeCa database in Denmark focuses on improving care quality for testicular cancer patients but faces issues with inaccuracies in manually registered relapse data and an ineffective algorithm for identifying relapses.
- - A study validated existing relapse data using medical records and developed a new algorithm, testing it on 250 patients and finding it highly effective in identifying relapses through national pathology and patient registers.
- - Results showed that 97.2% of relapse data was accurately recorded in DaTeCa, with the algorithm achieving 99.6% sensitivity, confirming that the database can effectively guide clinical quality assessments.
Prognostic factors for relapse in patients with clinical stage I testicular cancer: protocol for a Danish nationwide cohort study.
BMJ Open
October 2019
Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Introduction: Approximately one-fourth of patients with clinical stage I testicular germ cell cancer will relapse within 5 years of follow-up. Certain histopathological features in the primary tumour have been associated with an increased risk of relapse. The available evidence on the prognostic value of the risk factors, however, is hampered by heterogeneity of the study populations included and variable reporting of the histopathological features.
View Article and Find Full Text PDFCohort Profile: The Danish Testicular Cancer Late Treatment Effects Cohort (DaTeCa-LATE).
Front Oncol
February 2018
Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Unlabelled: The cohort was set up in order to analyze late effects in long-term testicular cancer survivors (TCS) and to contribute to the design of future follow-up programs addressing and potentially preventing late effects. Data for this cross-sectional study were collected between January 1, 2014, and December 31, 2016, among living Danish TCS and 60% agreed to participate in the cohort ( = 2,572). Mean time since testicular cancer (TC) diagnosis was 18 years (range 7-33) and mean age of participants was 53 years (range 25-95).
View Article and Find Full Text PDFThe Danish Testicular Cancer database.
Clin Epidemiol
October 2016
Department of Oncology 5073, Copenhagen University Hospital, Rigshospitalet, Copenhagen.
Aim: The nationwide Danish Testicular Cancer database consists of a retrospective research database (DaTeCa database) and a prospective clinical database (Danish Multidisciplinary Cancer Group [DMCG] DaTeCa database). The aim is to improve the quality of care for patients with testicular cancer (TC) in Denmark, that is, by identifying risk factors for relapse, toxicity related to treatment, and focusing on late effects.
Study Population: All Danish male patients with a histologically verified germ cell cancer diagnosis in the Danish Pathology Registry are included in the DaTeCa databases.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!